Day One Biopharmaceuticals, Inc.: M&A transaction — Day One completes acquisition of Mersana for $25/share cash plus CVRs up to $30.25

Day One Biopharmaceuticals, Inc.

Acquisition closed Jan 6, 2026; Mersana becomes wholly owned subsidiary of Day One.
Tender offer saw 60.57% of Mersana shares tendered; total cash consideration ~$128.8M.
Each Mersana share received $25 cash plus one non-tradable CVR with potential milestone payments up to $30.25/share.
CVR milestones include FDA breakthrough designation and sales thresholds for emiltatug-ledadotin (Emi-Le).
Mersana common stock to be delisted from Nasdaq effective Jan 6, 2026.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Day One Biopharmaceuticals, Inc. completed an acquisition involving Mersana Therapeutics, Inc. for $25.00 per Target Share plus one non-tradable contingent value right (closed 2026-01-06).

Action: acquisition
Counterparty: Mersana Therapeutics, Inc.
Consideration: $25.00 per Target Share plus one non-tradable contingent value right
Closing: 2026-01-06

Exact text from the filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Day One Biopharmaceuticals, Inc. entered into CVR Agreement with Rights Agent (effective 2026-01-06).

Action: entry
Counterparty: Rights Agent
Effective: 2026-01-06

Exact text from the filing

on January 6, 2026, the Parent and the Rights Agent entered into the CVR Agreement governing the terms of the CVRs issued pursuant to the Offer and the Merger

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001104659-26-001127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.